PPARA and cancer: Since RXR forms a permissive heterodimeric complex with PPAR, and the activationof PPARγexerts antigrowth effects in cancer cells [4–6], it seems to be reasonable that thecombination of RXR and PPARγagonists may offer new therapeutic strategies for various types of humanmalignancies.